Age Differences in the Effects of Cannabis on Simulated Driving

NCT ID: NCT04325958

Last Updated: 2024-04-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-27

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epidemiological studies suggest that the use of cannabis is associated with an increase in the risk of motor vehicle collisions. It is also known that younger users may be at increased risk for motor vehicle collisions. Further, the frequency with which cannabis is used may be an important variable in determining the effects of cannabis on driving. The purpose of the present study will be to investigate the effects of cannabis on simulated driving in young as compared to middle-aged drivers. Half of the participants will be occasional users of cannabis and half will be frequent users of cannabis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Epidemiological studies have established that the use of cannabis can increase the risk of a motor vehicle collision. A number of variables can influence the effects of cannabis on driving. For example, frequent users of cannabis have been shown to have different cognitive and physiological responses to cannabis as compared to occasional users. In addition, we know that younger drivers are more likely to be involved in motor vehicle collisions after alcohol use as compared to older users. The contribution of age and experience with cannabis on cannabis-mediated effects on driving have yet to be delineated in laboratory studies. The purpose of the present investigation will be to determine whether cannabis has different effects on driving in young, as compared to middle aged, drivers. Half of each age group will be occasional users of cannabis and the other half will be frequent users.

Eligible participants will attend the laboratory for two test sessions; in one session they will smoke a cannabis cigarette and in the other they smoke a placebo cigarette. Participants will drive a driving simulator before and after smoking the cigarette. Blood for measurement of THC and metabolites will also be collected before smoking the cigarette and at a number of times after smoking. Subjective and cognitive tasks will be completed before and after smoking.

It is hoped that the findings of this study will help to inform public perception and policy into the potential effects of cannabis on driving.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Participants will complete a session with active cannabis and a session with placebo cannabis.

Order of sessions is randomized.

Participants and Investigator are blinded.

Allocation to arms is not randomized. Arms are based on their age.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Age group 19 to 25

Participants will complete two sessions: one where they drive the simulator before and after smoking a placebo cannabis cigarette (\<1% THC), the other where they drive the simulator before and after smoking an active cannabis cigarette (15% ± 5% THC).

Group Type OTHER

Cannabis

Intervention Type DRUG

750mg cigarette of plant material

Placebos

Intervention Type DRUG

750mg cigarette of plant material

Age group 35 to 45

Participants will complete two sessions: one where they drive the simulator before and after smoking a placebo cannabis cigarette (\<1% THC), the other where they drive the simulator before and after smoking an active cannabis cigarette (15% ± 5% THC).

Group Type OTHER

Cannabis

Intervention Type DRUG

750mg cigarette of plant material

Placebos

Intervention Type DRUG

750mg cigarette of plant material

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cannabis

750mg cigarette of plant material

Intervention Type DRUG

Placebos

750mg cigarette of plant material

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Marijuana Dummy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 19-25 or 35-45 years of age;
* Use of smoked cannabis at least once in the past 6 months.
* Use of smoked or vaped cannabis primarily for recreational purposes on up to 1 day per week or on at least 6 days per week in the past 3 months;
* Holds a class G or G2 Ontario driver's licence (or equivalent from another jurisdiction) for at least 12 months;
* Willing to abstain from using alcohol for 24 hours and cannabis for 72 hours prior to Practice and Test Sessions;
* Willing to abstain from all other drugs not prescribed for medical purposes for 48 hours prior to Practice and Test Sessions;
* Resides within Toronto (study site) or can reside with friends/family in Toronto after a Test Session; this area may be extended to the Greater Toronto area if recruitment challenges arise;
* Participant willing to use appropriate contraception until their participation in the study is completed;
* Provides written and informed consent.

Exclusion Criteria

* Use of cannabis primarily for therapeutic purposes, or equally for therapeutic and recreational purposes;
* Diagnosis of medical condition that contraindicates use of cannabis determined by self-report as judged by the Principal Investigator and a study physician; this includes a history of hypersensitivity to cannabinoids smoke, respiratory disease and/or severe cardiovascular, cerebrovascular, renal or liver disease, and bleeding disorders. Smoking cannabis is not recommended for individuals with respiratory diseases, and they will be excluded;
* Diagnosis of psychiatric condition that contraindicates use of cannabis determined by self-report or SCID-5;
* Participants of childbearing potential: Pregnancy (point-of-care test) or breastfeeding;
* Meets criteria for current or lifetime alcohol or other substance use disorder (DSM-5), except tobacco use disorder and caffeine use disorder;
* Is a regular user of medications that affect brain function (based on self-report); this includes concomitant therapy with sedative-hypnotics or other psychoactive drugs
* Use of anti-hypertensives;
* First-degree relative diagnosed with schizophrenia or another psychotic disorder.
* Participation in a past driving study at CAMH (to limit practice effects).
* Participation in a clinical study concurrent with their participation in this study.
Minimum Eligible Age

19 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre for Addiction and Mental Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christine Wickens, PhD

Role: PRINCIPAL_INVESTIGATOR

Centre for Addiction and Mental Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre for Addiction and Mental Health

Toronto, Ontario, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christine Wickens, PhD

Role: CONTACT

416 535-8501 ext. 34711

Gina Stoduto

Role: CONTACT

416 535-8501 ext. 34499

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Christine Wickens, PhD

Role: primary

416-535-8501 ext. 34711

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

048/2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Detection of Cannabis Impairment With an Eye Tracker
NCT03813602 COMPLETED PHASE1/PHASE2
Acute Effects of THC in Older Adult
NCT06948136 RECRUITING PHASE1
Cannabis Effects as a Function of Sex
NCT04385082 RECRUITING PHASE1
A Brief Intervention for Cannabis Use
NCT06395389 RECRUITING NA